CCI clears deal involving Sekhmet Pharmaventures and Optimus Drugs
Under the transaction, Sekhmet would buy a majority shareholding in Optimus Drugs
The Competition Commission of India (CCI) recently approved the proposed deal involving Sekhmet Pharmaventures and Optimus Drugs.
Under the transaction, Sekhmet would buy a majority shareholding in Optimus Drugs.
The fair trade regulator also approved Optimus Drug’s acquisition of shareholding in Optimus Pharma and Optimum Life Science.
In a tweet, the watchdog said it has approved acquisition of majority shareholding in Optimus Drugs by Sekhmet Pharmaventures as well as Optimus Drug’s purchase of stakes in Optimus Pharma and Optimus Life Science.
In May, a consortium of private equity funds led by PAG announced that they will acquire a controlling stake in Hyderabad-based pharma company Optimus Drugs for Rs 2,000 crore.
Edits by EP News Bureau